Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Though there were no historical benchmarks to gauge the response, the Dollar Index could fall more than 5%. Sterling edged higher versus the euro but remained weaker against a firmer dollar after the ...

The airline reset its profit guidance for the year, citing improved travel appetite after economic turmoil and flight disruptions depressed bookings this spring. Coca-Cola says more details are to ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics has established itself as a leader in the development of treatments for DMD and other rare neuromuscular disorders. The company’s portfolio includes FDA-approved exon-skipping ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Sarepta Therapeutics has established itself as a leader in the development of treatments for DMD, with a portfolio that includes FDA-approved exon-skipping therapies such as Exondys 51, Vyondys 53, ...